Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Endometrial hyperplasia risk in relation to recent use of oral contraceptives and hormone therapy.

Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS.

Ann Epidemiol. 2009 Jan;19(1):1-7. doi: 10.1016/j.annepidem.2008.08.099.

3.

Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history.

Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS.

Am J Epidemiol. 2008 Sep 15;168(6):563-70; discussion 571-6. doi: 10.1093/aje/kwn168. Epub 2008 Aug 5.

4.
5.

Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.

Lacey JV Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C.

Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1724-31.

6.

Oral contraceptives, hormone replacement therapy and breast cancer risk: a cohort study of 16 928 women 48 years and older.

Thorbjarnardottir T, Olafsdottir EJ, Valdimarsdottir UA, Olafsson O, Tryggvadottir L.

Acta Oncol. 2014 Jun;53(6):752-8. doi: 10.3109/0284186X.2013.878471. Epub 2014 Jan 24.

PMID:
24460068
7.

Estrogen-progestin replacement therapy and endometrial cancer.

Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM.

J Natl Cancer Inst. 1997 Aug 6;89(15):1110-6.

PMID:
9262248
8.
9.

Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.

Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, Berchuck A, Barrett JC, Rodriguez GC.

Gynecol Oncol. 2006 Nov;103(2):535-40. Epub 2006 Jun 5.

PMID:
16740300
10.

Incidence of thyroid cancer in women in relation to reproductive and hormonal factors.

McTiernan AM, Weiss NS, Daling JR.

Am J Epidemiol. 1984 Sep;120(3):423-35.

PMID:
6475918
11.

Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.

van Leeuwen FE.

Acta Endocrinol (Copenh). 1991;125 Suppl 1:13-26. Review.

PMID:
1801500
12.
13.

Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer.

Jick SS, Hagberg KW, Kaye JA, Jick H.

Obstet Gynecol. 2009 Jan;113(1):74-80. doi: 10.1097/AOG.0b013e31818fdde4.

PMID:
19104362
14.

Effects of hormone therapy on the endometrium.

Deligdisch L.

Mod Pathol. 1993 Jan;6(1):94-106. Review.

PMID:
8426860
15.

Progestogens in cardiovascular diseases: an introduction to the epidemiologic data.

Mann JI.

Am J Obstet Gynecol. 1982 Mar 15;142(6 Pt 2):752-7.

PMID:
7065056
16.

Hormone therapy in postmenopausal women and risk of endometrial hyperplasia.

Furness S, Roberts H, Marjoribanks J, Lethaby A.

Cochrane Database Syst Rev. 2012 Aug 15;(8):CD000402. doi: 10.1002/14651858.CD000402.pub4. Review.

PMID:
22895916
17.

The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy.

Sturdee DW, Ulrich LG, Barlow DH, Wells M, Campbell MJ, Vessey MP, Nielsen B, Anderson MC, Bragg AJ.

BJOG. 2000 Nov;107(11):1392-400. Erratum in: BJOG 2001 Mar;108(3):335.

18.

Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.

Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H.

Cochrane Database Syst Rev. 2004;(3):CD000402. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD000402.

PMID:
15266429
19.

Estrogen and progestin components of oral contraceptives: relationship to vascular disease.

Carr BR, Ory H.

Contraception. 1997 May;55(5):267-72. Review.

PMID:
9220222
20.

An estrogen-induced endometrial hyperplasia mouse model recapitulating human disease progression and genetic aberrations.

Yang CH, Almomen A, Wee YS, Jarboe EA, Peterson CM, Janát-Amsbury MM.

Cancer Med. 2015 Jul;4(7):1039-50. doi: 10.1002/cam4.445. Epub 2015 Mar 23.

Supplemental Content

Support Center